Biomarin Pharmaceutical Inc (NAS:BMRN)
$ 67.27 0.2 (0.3%) Market Cap: 12.82 Bil Enterprise Value: 12.45 Bil PE Ratio: 40.28 PB Ratio: 2.37 GF Score: 69/100

Biomarin Pharmaceutical Inc at Jefferies London Healthcare Conference Transcript

Nov 21, 2019 / 01:20PM GMT
Release Date Price: $77.07 (-0.46%)
Eun Kyung Yang
Jefferies LLC, Research Division - MD & Senior Equity Research Analyst

Good afternoon. This is Eun Yang, a biotech analyst with Jefferies based in New York. Our next presenting company is BioMarin. I'm sure that almost all of you know the -- know BioMarin quite well, and it doesn't really need any kind of introduction from my part.

This presentation is going to be a kind of a hybrid format where J.J. is going to provide us with an overview of the company, about 10 minutes. Then we are going to be doing Q&A. So presenting from BioMarin is J.J. Bienaimé, CEO and Chairman of the company. J.J.?

Jean;Jacques BienaimÃ;BioMarin Pharmaceutical Inc.;Chairman;CEO

©,-&

Thank you. Good afternoon, everybody. Pleasure to be here. So I only have like 5 slides, and then we'll move to Q&A. And so just to -- big, big picture of where we come from, where we're going. So this company was definitely built over the last 21 years now on ultra-orphan disorders, mainly around lysosomal

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot